Gossamer Bio vs Verastem
GOSS and VSTM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GOSS and VSTM compare
Gossamer Bio is the larger company, worth 8.0 times as much as Verastem ($5.4B against $671M).
Verastem keeps more of each dollar of sales as profit, with a net margin of −232% compared with −235% at Gossamer Bio.
Verastem scores higher on the StockData Score (3 against 1 for Gossamer Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GOSS | VSTM |
|---|---|---|
| Size and price | ||
| Market cap | $5.4B | $671M |
| Share price | $11.04 | $7.41 |
| Change, 1 year | −94.9% | −1.9% |
| Change, 5 years | −98.7% | −77.0% |
| Beta (5Y) | 2.33 | 2.66 |
| Employees | 161 | 102 |
| StockData Score | ||
| Total score | 1 | 3 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 1 |
| Performance score | 0 | 1 (better) |
| Health score | 0 | 1 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 101× | 7.7× (better) |
| P/B | – | 13.4× |
| FCF yield | −3.0% | – |
| Growth | ||
| Revenue growth (TTM) | 32.4% | – |
| Revenue growth, 5Y average | – | −19.0% |
| Profitability | ||
| Operating margin | −312% | −183% (better) |
| Net margin | −235% | −232% (better) |
| FCF margin | −305% | – |
| Return on equity | – | −471% |
| Financial health | ||
| Interest coverage | −15.2× (better) | −108.3× |
| Current ratio | 0.53 | 2.25 (better) |
| Altman Z-score | −15.26 | −7.37 (better) |
| Piotroski F-score | 1 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 0.98% | 109% |
| Held by insiders | 2.8% | 1.8% |
| Insider net buying, 12 months | – | −$816K |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 0.28% | 22.1% |
Go deeper
- GOSS stock overview
- GOSS income statement
- GOSS valuation and score
- VSTM stock overview
- VSTM income statement
- VSTM valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.